Contents, Vol. 42, 1985
H Ohtani, James M. Slater, P. Rubin, L.S. Constine(Women & Children's Hospital of Buffalo), K. Klinga, Richard S. Porensky, Bonaventura Lazzaro(Tumori Foundation), Daila S. Gridley, Helmut König(Johannes Gutenberg University Mainz), Paul H. Sugarbaker(American Institute for Cancer Research), Pablo E. Brockmann, S. Domschke, N. Nakissa, David W. Mantik, Frej Stenbäck(University of Oulu), M Volm, James D. Kettering(Loma Linda University), Leila Risteli, Paola Papaldo(Cancer Institute (WIA)), B. Runnebaum, W. Domschke, Jürgen Mattern, Juha Risteli, Joseph P. Fanning, Delvyn C. Case, Robert Burns, Ken Koshiba, Wilbert Matthews, Eiichi Furusawa, Robert L. Nutter, Shinobu Furusawa, Ch. Ell, Masayuki Saito(Chiba University), Luigi Di Lauro, Roberta Strohl, Veli-Matti Wasenius, Massimo Lopez
Cited by 0
Related Papers
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial
|The Lancet|2015|202
Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. Italian Multicentre Breast Study with Epirubicin.
|Journal of Clinical Oncology|1988|168
Survival of Human Ovarian Follicles from Fetal to Adult Life: Apoptosis, Apoptosis-Related Proteins, and Transcription Factor GATA-41
|The Journal of Clinical Endocrinology & Metabolism|2001|168
Lonidamine: Efficacy and safety in clinical trials for thetreatment of solid tumors
|Drugs of today|2003|168